Headlands Technologies 将罕见病专家 PTC Therapeutics 的股份增加了 326,000 美元。 Headlands Technologies boosts stake in PTC Therapeutics, a rare disease specialist, by $326,000.

通过购买额外的价值326,000美元的股票, 显著增加了PTC Therapeutics的股份, Headlands Technologies has significantly increased its stake in PTC Therapeutics, a biopharmaceutical firm specializing in rare diseases, by purchasing additional shares worth $326,000. PTC 治疗疗法为诸如Duchenne肌肉萎缩和脊椎肌肉萎缩等情况提供治疗。 PTC Therapeutics offers treatments for conditions like Duchenne muscular dystrophy and spinal muscular atrophy. 股票得到分析员的支持,平均评为“中价购买”,价格目标为63.77美元。 The stock has seen analyst support, with an average "Moderate Buy" rating and a price target of $63.77. 公司主管最近进行的交易包括CEO Eric Pauwels和EVP Lee Scott Golden的销售。 Recent transactions by company executives include sales by CEO Eric Pauwels and EVP Lee Scott Golden.